Sareum Holdings plc

Equities

SAR

GB00BMC3RJ87

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 15:06:09 23/05/2024 BST			5-day change	1st Jan Change
33.4 ^GBX	+2.77%		-10.34%	-43.87%

04-23	Sareum Issues Shares to Settle Facility with RiverFort	MT
04-19	Sareum falls as issues shares to RiverFort Global	AN

Sareum Holdings plc Provides Earnings Guidance for the Year Ended June 30, 2017

August 22, 2017 at 07:00 am

Sareum Holdings plc provided earnings guidance for the year ended June 30, 2017. For the year, the company expects that the profit for the year after tax and cash at bank, to be ahead of market expectations.

Latest news about Sareum Holdings plc

Sareum Issues Shares to Settle Facility with RiverFort	04-23	MT
Sareum falls as issues shares to RiverFort Global	04-19	AN
Northcoders launches bootcamp; Schroder invests	04-04	AN
Sareum ups retail offer; SThree nabs former ITV exec	04-02	AN
Sareum to Increase Retail Offer After Oversubscription	04-02	MT
EARNINGS AND TRADING: Northamber loss widens; Ethernity contract boost	03-28	AN
Sareum Holdings plc Reports Earnings Results for the Half Year Ended December 31, 2023	03-28	CI
Sareum Holdings touts new patent allowance for autoimmune therapy	03-15	AN
Sareum Bags European Patent for Kinase Inhibitor for Autoimmune Disease	03-15	MT
Sareum shares slump on widened loss and funding talks	03-12	AN
Sareum Wraps Up Single Ascending Dose, Food Effect Study in Early-stage Trial of Autoimmune Disease Drug	02-15	MT
Sareum hails safety profile for SDC-1801 after phase 1 trial	02-15	AN
AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets	02-15	AN
Sareum Holdings plc Announces Completion of the Single Ascending Dose Part and the Food Effect Study of its Phase 1a Clinical Trial for the Lead Programme SDC-1801	02-15	CI
Sareum's Partner Signs Deal with US Biopharma Company for Cancer Growth Blockers	01-02	MT
London stocks make largely soft start to 2024	01-02	AN
AIM WINNERS & LOSERS: LungLife AI soars on test; Plexus falls on deal	01-02	AN
Sareum soars as partner agrees SRA737 licence with US biopharma firm	01-02	AN
EARNINGS AND TRADING: CleanTech raises GBP520,000 in open offer	12-14	AN
Sareum Holdings plc Provides Update on Operational Activities and Pipeline Progress	12-14	CI
Transcript : Sareum Holdings plc - Shareholder/Analyst Call	12-14
Sareum Holdings draws down on equity prepayment facility	11-23	AN
Sareum Draws Down GBP300,000 from Equity Prepayment Facility	11-23	MT
Sareum Doses First Subjects in Food Effects Part of Lead Asset Trial	11-09	MT
EARNINGS AND TRADING: MetalNRG hails Gold Ridge findings	11-09	AN

Chart Sareum Holdings plc

Duration

Period

More charts

Company Profile

Sareum Holdings plc is a United Kingdom-based biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's internal programs focus on distinct dual tyrosine kinase 2 (TYK2)/ Janus kinase 1 (JAK1) inhibitors, which are progressing through preclinical development as therapies for autoimmune diseases and cancers. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with an initial focus on psoriasis. It is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. The Company also has an interest in SRA737, an orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and a central mediator of the DNA damage response (DDR) network.

Sector

Biotechnology & Medical Research

Calendar

14/10/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.325 GBP

Average target price

1.76 GBP

Spread / Average Target

+441.54%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SAREUM HOLDINGS PLC	-43.87%	44.65M
VERTEX PHARMACEUTICALS INCORPORATED	+10.56%	115B
REGENERON PHARMACEUTICALS, INC.	+12.31%	106B
BIONTECH SE	-5.27%	24.69B
ARGENX SE	-1.43%	21.97B
GENMAB A/S	-4.87%	19.27B
BEIGENE, LTD.	-11.04%	17.56B
WUXI APPTEC CO., LTD.	-39.36%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+5.95%	14.03B
SAREPTA THERAPEUTICS, INC.	+33.53%	12.13B

Bio Therapeutic Drugs